These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31914201)

  • 21. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial.
    Melichar B; Procházková-Študentová H; Vitásková D
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1253-61. PubMed ID: 23136836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
    Lee CH; DiNatale RG; Chowell D; Krishna C; Makarov V; Valero C; Vuong L; Lee M; Weiss K; Hoen D; Morris L; Reznik E; Murray S; Kotecha R; Voss MH; Carlo MI; Feldman D; Sachdev P; Adachi Y; Minoshima Y; Matsui J; Funahashi Y; Nomoto K; Hakimi AA; Motzer RJ; Chan TA
    Mol Cancer Res; 2021 Sep; 19(9):1510-1521. PubMed ID: 34039647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenvatinib for the treatment of renal cell carcinoma.
    Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
    Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoimmunotherapy of metastatic renal cell carcinoma.
    Bukowski RM
    Cancer Invest; 1999; 17(6):460-1. PubMed ID: 10434957
    [No Abstract]   [Full Text] [Related]  

  • 26. Lenvatinib for the treatment of kidney cancer.
    Študentová H; Vitásková D; Melichar B
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
    Latteux G; Lebdai S; Hoarau N; Abadie-Lacourtoisie S; Delva R; Chautard D; Azzouzi AR; Bigot P
    Prog Urol; 2013 Mar; 23(3):184-94. PubMed ID: 23446283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In focus: bevacizumab for renal cell carcinoma.
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
    [No Abstract]   [Full Text] [Related]  

  • 30. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
    De Lisi D; De Giorgi U; Lolli C; Schepisi G; Conteduca V; Menna C; Tonini G; Santini D; Farolfi A
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):461-467. PubMed ID: 29557694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reply to T.G. Karrison.
    Nosov DA; Strahs AL
    J Clin Oncol; 2013 Feb; 31(6):814-5. PubMed ID: 23544201
    [No Abstract]   [Full Text] [Related]  

  • 32. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.
    Schwartz C; Pfanzelter N; Kuzel TM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e903-e906. PubMed ID: 28624319
    [No Abstract]   [Full Text] [Related]  

  • 33. Sorafenib [corrected] in kidney cancer.
    Escudier B
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
    [No Abstract]   [Full Text] [Related]  

  • 34. Kidney cancer: SWITCHing inconsequential.
    Thoma C
    Nat Rev Urol; 2015 Jun; 12(6):305. PubMed ID: 25986758
    [No Abstract]   [Full Text] [Related]  

  • 35. Estimation of progression-free survival in the randomized discontinuation trial design.
    Karrison TG
    J Clin Oncol; 2013 Feb; 31(6):814. PubMed ID: 23319693
    [No Abstract]   [Full Text] [Related]  

  • 36. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.
    Matsubara N; Naito Y; Nakano K; Fujiwara Y; Ikezawa H; Yusa W; Namiki M; Okude T; Takahashi S
    Int J Urol; 2018 Nov; 25(11):922-928. PubMed ID: 30129060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
    Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
    Flaherty KT
    Cancer; 2010 Jan; 116(1):4-7. PubMed ID: 19890962
    [No Abstract]   [Full Text] [Related]  

  • 39. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
    Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib-Sunitinib Sequence: The Jury Is Out.
    Albiges L; Escudier B
    Eur Urol; 2015 Nov; 68(5):848-9. PubMed ID: 26184972
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.